NCT04470986|Unknown
Study on Inferior Vena Cava Thrombosis
SIVECT
International Registry on the Diagnosis and Treatment of Inferior Vena Cava Thrombosis
Loading search results
SIVECT
International Registry on the Diagnosis and Treatment of Inferior Vena Cava Thrombosis
Sponsor study identifier
observational
200
0 countries
N/A
Study Start
June 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This study will focus on patients having inferior vena cava (IVC) thrombosis, either with or without thrombosis in other veins. The purpose of this study is to assess risk factors, safety and effectiveness of treatment options, and outcomes of patients with IVC thrombosis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 8, 2020
Actual (reported)July 14, 2020
Actual (reported)June 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Rates of venous thromboembolism (VTE) recurrence
Recurrence of any venous thrombosis (not previously diagnosed)
2 Years
Rate of all cause mortality
Mortality (patient's death) from any cause
2 Years
Rates of major bleeding
Major bleeding per International Society on Thrombosis and Haemostasis criteria Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692- 4.
2 Years
Rates of thrombosis recanalization
2 Years
Rates of post-thrombotic syndrome (PTS)
2 Years
Rates of clinically relevant non-major bleeding
2 Years
Patients with an objective diagnosis of IVC thrombosis, either with or without proximal lower extremity DVT
First Submitted
July 8, 2020
First Posted
July 14, 2020
Study Start
June 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
Contact the study team to confirm eligibility.
December 31, 2023
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 22, 2020
Record last verified: 2020-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: